Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months

BACKGROUND: Respiratory syncytial virus (RSV) remains a leading cause of pediatric morbidity, with no approved vaccine. We assessed the safety and immunogenicity of the Ad26.RSV.preF vaccine candidate in adults and children. METHODS: In this randomized, double-blind, phase 1/2a, placebo-controlled s...

Descripción completa

Detalles Bibliográficos
Autores principales: Stuart, Arabella S V, Virta, Miia, Williams, Kristi, Seppa, Ilkka, Hartvickson, Robyn, Greenland, Melanie, Omoruyi, Edmund, Bastian, Arangassery Rosemary, Haazen, Wouter, Salisch, Nadine, Gymnopoulou, Efi, Callendret, Benoit, Faust, Saul N, Snape, Matthew D, Heijnen, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796164/
https://www.ncbi.nlm.nih.gov/pubmed/36259542
http://dx.doi.org/10.1093/infdis/jiac407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796164/
https://www.ncbi.nlm.nih.gov/pubmed/36259542
http://dx.doi.org/10.1093/infdis/jiac407

Ejemplares similares